For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230209:nRSI4966Pa&default-theme=true
RNS Number : 4966P Royal Bank of Canada 09 February 2023
Royal Bank of Canada
February 9, 2023
Publication of Prospectus
Not for release, publication or distribution, directly or indirectly, in or
into the United States.
Royal Bank of Canada has agreed to EUR28,000,000 1.034 per cent. Senior Notes
due January 25, 2034 (to be consolidated and form a single series with
EUR450,000,000 1.034 per cent. Senior Notes due January 25, 2034 issued on
January 25, 2022 (Tranche 1) and EUR40,000,000 1.034 per cent. Senior Notes
due January 25, 2034 issued on October 20, 2022 (Tranche 2)), Series 64148,
Tranche 3 (the "Notes") pursuant to its Programme for the Issuance of
Securities (the "Programme").
The following document constitutes the final terms dated February 9, 2023 (the
"Final Terms") relating to the admission to trading of the Notes for purpose
of Article 8 of Regulation (EU) 2017/1129 and as it forms part of domestic law
by virtue of the European Union (Withdrawal) Act 2018 (EUWA) and must be
read in conjunction with the Terms and Conditions contained in the Prospectus
dated July 23, 2021 which are incorporated by reference in the Prospectus
dated July 29, 2022, as supplemented by the 1(st) Supplementary Notes Base
Prospectus dated August 25, 2022 and the 2(nd) Supplementary Notes Base
Prospectus dated December 20, 2022 relating to the Programme (together, the
"Prospectus"). Full information on Royal Bank of Canada and the offer of the
Notes is only available on the basis of the combination of the Final Terms and
the Prospectus.
DISCLAIMER - INTENDED ADDRESSEES
Please note that the information contained in the Prospectus and the Final
Terms, may be addressed to and/or targeted at persons who are residents of
particular countries (specified in the Prospectus) only and is not intended
for use and should not be relied upon by any person outside these countries
and/or to whom the offer contained in the Final Terms is not addressed.
Prior to relying on the information contained in the Final Terms you must
ascertain from the Prospectus, as supplemented by these Final Terms, whether
or not you are part of the intended addressees of the information contained
therein.
The Notes have not been and will not be registered under the United States
Securities Act of 1933, as amended (the "Securities Act") or the securities
laws of any state of the US and are subject to US tax law requirements.
Subject to certain exceptions, the Notes may not be offered, sold or delivered
in or into the United States or to or for the account or benefit of a "US
person" (as defined in Regulation S under the Securities Act). No public
offering of the Notes is being made in the United States. This announcement
does not constitute an offer to sell or a solicitation to buy securities in
the United States or in any other jurisdiction where such offer or
solicitation would be unlawful.
Your right to access this service is conditional upon complying with the above
requirement.
UK MiFIR professionals / ECPs-only / No PRIIPs or UK PRIIPs KID - Manufacturer
target market (UK MiFIR product governance) is eligible counterparties and
professional clients only (all distribution channels). No PRIIPs or UK
PRIIPs key information document (KID) has been prepared as not available to
retail in EEA or the UK.
To view the full document, please paste the following URLs into the address
bar of your browser.
http://www.rns-pdf.londonstockexchange.com/rns/4966P_1-2023-2-9.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/4966P_1-2023-2-9.pdf)
For further information, please contact
Erin Dion
Assistant General Counsel
Royal Bank of Canada
Telephone Number: (416) 974-4103
Fax Number: (416) 955-2032
Email: erin.dion@rbc.com
END
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END PDIGZGGZVLNGFZM